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Abstract
Background: Dementia and diabetes mellitus are common long-term conditions and co-exist in a large number
of older people. People living with dementia (PLWD) may be less able to manage their diabetes, putting them at
increased risk of complications such as hypoglycaemia. The aim of this review was to identify key mechanisms
within different interventions that are likely to improve diabetes outcomes in PLWD.
Methods: This is a realist review involving scoping of the literature and stakeholder interviews to develop
theoretical explanations of how interventions might work, systematic searches of the evidence to test and develop
the theories and their validation with a purposive sample of stakeholders. Twenty-six stakeholders — user/patient
representatives, dementia care providers, clinicians specialising in diabetes or dementia and researchers — took
part in interviews, and 24 participated in a consensus conference.
Results: We included 89 papers. Ten focused on PLWD and diabetes, and the remainder related to people
with either dementia, diabetes or other long-term conditions. We identified six context-mechanism-outcome
configurations which provide an explanatory account of how interventions might work to improve the management
of diabetes in PLWD. This includes embedding positive attitudes towards PLWD, person-centred approaches to care
planning, developing skills to provide tailored and flexible care, regular contact, family engagement and usability of
assistive devices. An overarching contingency emerged concerning the synergy between an intervention strategy,
the dementia trajectory and social and environmental factors, especially family involvement.
Conclusions: Evidence highlighted the need for personalised care, continuity and family-centred approaches,
although there was limited evidence that this happens routinely. This review suggests there is a need for a flexible
service model that prioritises quality of life, independence and patient and carer priorities. Future research on the
management of diabetes in older people with complex health needs, including those with dementia, needs to
look at how organisational structures and workforce development can be better aligned to their needs.
Trial registration: PROSPERO, CRD42015020625. Registered on 18 May 2015.
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Background
Rates of diabetes in people living with dementia
(PLWD) are between 13% and 20% [1]. Worldwide
there are an estimated 35.6 million PLWD. By 2050
this number will rise to more than 115 million [2].
Although there are differences in the physical and
cognitive effects of the different types of dementias,
all are progressive, involve increasing physical and
mental deterioration and lead to a person with
dementia becoming increasingly dependent. In PLWD
the likelihood of diabetes-related complications, such
as hypoglycaemic episodes, cardiovascular conditions
and amputations may be increased [3, 4]. This hap-
pens because dementia has an impact on an individ-
ual’s ability to administer medication, regulate eating
habits and recognise and treat hypoglycaemia [5–7].
Furthermore, there appears to be a reciprocal
relationship between hypoglycaemia, dementia and
frailty [8, 9]. The impact on health and social care
economies and on patients and their families is
considerable [10].
The delivery of health and social care for this group
is complex and challenging [11]. Despite this, there is
currently no systematic approach to the management
of diabetes and dementia [12]. In the UK there is a gap
in provision of services in mental health trusts for
diabetes care and similarly a gap in acute hospital
trusts for dementia care [12]. Guidance on the
management of diabetes in PLWD outlines a number
of recommendations, including better case finding of
both conditions, better training for staff, adequate
support for family carers and care that is tailored to
the need of the individual [12, 13]. However, currently
there is little research evaluating interventions to
improve the management of diabetes in PLWD; many
diabetes-related studies specifically exclude PLWD.
There is a need to consider what kind of interven-
tions are required for the effective management of
diabetes in PLWD, including how interventions work,
for whom and in what contexts. Interventions
designed to improve the management of diabetes in
PLWD are likely to be multicomponent, specific to
different stages of the dementia trajectory and
dependent on the behaviours and choices of those de-
livering and receiving the care. Realist synthesis is a
systematic, theory-driven approach that aims to make
explicit the mechanism(s) of how and why complex
interventions work (or not) in particular settings or
contexts [14–16]. Realist synthesis takes account of a
broad and eclectic evidence base, including experien-
tial and clinical knowledge. The aim of this review
was to identify programme mechanisms to improve
the management of diabetes in PLWD and to identify
areas needing further research.
Methods
Rationale for using realist approach
Realist review is a theory-driven interpretive approach to
evidence synthesis that endeavours to unpack the ‘black
box’ of how complex interventions work [14, 15, 17].
The purpose of this review was to develop an explana-
tory account or programme theory about ‘what works’ in
the management of diabetes in PLWD, and in what con-
texts. Explanatory accounts comprise configurations of
context (the background conditions in which interven-
tions are delivered and in which mechanisms are trig-
gered), mechanism (the responses or changes that are
brought about through a programme within a particular
context) and outcomes. Definitions of key realist termin-
ology used in the review are provided in Box 1. These
context-mechanism-outcome (CMO) configurations are
developed iteratively through data collection, theorising
and stakeholder engagement. This account follows the
Realist And Meta-narrative Evidence Syntheses: Evolving
Box 1: Definitions of realist terms and how they have
been applied in the review
 Context (C): This refers to the ‘backdrop’ conditions, for
example provision of training in diabetes and/or dementia
care delivery systems. Context can be broadly understood as
any condition that triggers and/or modifies the behaviour of
a mechanism
 Mechanism (M): A mechanism is the generative force
triggered in particular contexts that leads to outcomes. It
often denotes the reasoning (cognitive or emotional) of the
various ‘actors’, i.e. people living with dementia and diabetes
(PLWDD), relatives and healthcare professionals.
Mechanisms are linked to, but are not the same as, a
service’s strategies or interventions. Identifying the
mechanisms goes beyond describing ‘what happened’ to
theorizing ‘why it happened, for whom and under what
circumstances’
 Outcomes (O). The outcome is a result of the interaction
between a mechanism and its triggering context. Outcomes
may include greater engagement in self-management behav-
iours or a reduction in adverse events
 Programme theory: Those ideas about what needs to be
changed or improved in how diabetes is managed for PLWD,
what needs to be in place to achieve improvement(s) and
how programmes are believed to work. The programme
theory specifies what is being investigated and the elements
and scope of the review
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Standards (RAMESES) publication standards for realist
syntheses [14]. A fuller version of the methods is
published elsewhere [18]. In the protocol we specified
that we would include people living in the community, a
care home or other long-term setting. However, in the
scoping phase the inclusion criteria were refined to
exclude PLWD in care homes because there were felt to
be significant differences between the environments.
The change was agreed upon with the Project Advisory
Group.
Phase 1: defining the scope of the realist review— concept
mining and theory development
To develop our initial programme theories we scoped
published and grey literature (see Table 1) and inter-
viewed 19 content experts. This was followed by a work-
shop where the project team began to map and
prioritise the identified theory. Content experts included
clinicians with a special interest in either diabetes or de-
mentia; providers of care in primary or secondary care;
user representatives, including recipients of care, family
carers and relevant diabetes or dementia charities; and
academics and those involved in developing education
and guidance for older people with diabetes. Interviews
were conducted face to face or via telephone, using an
interview schedule guided by realist principles [19]; they
were audio recorded and transcribed. Ethical approval
was obtained from the University of Hertfordshire
Health and Human Sciences Ethics Committee with
delegated authority (CHSK/SF/UH/00106).
Next we developed a series of explanatory accounts
containing ‘If-Then’ statements [20]. ‘If-Then’ state-
ments are the identification of an intervention/activity
linked to outcome(s), and they contain references to
contexts and mechanisms (though these may not be
very explicit at this stage). The ‘If-Then’ statements
helped to focus the process of considering ideas and
assumptions about how interventions work and test-
ing them against the evidence. Initially we generated
20 ‘If-Then’ statements which, after further discussion,
were synthesised to three. We then mapped ideas
about ‘good’ diabetes care against barriers for PLWD,
potential interventions and emerging theory. This
became Theory Area (TA) 1 — clinically based
approach. Additional theory areas around supportive
partnerships (TA 2) and co-production (TA 3) were
developed to reflect other areas identified in the
scoping.
Phase 2: retrieval, review and synthesis
In Phase 2 we undertook systematic evidence searches
to test and develop the theories identified in Phase 1.
The main inclusion criteria were:
 PLWD of any type or severity and type 1 or 2
diabetes, resident in the community
 Any intervention designed to promote the
management of diabetes in PLWD and the
prevention of potential adverse effects associated
with poorly managed diabetes
 Studies that provide evidence on barriers and
facilitators to the implementation and uptake of
interventions designed to improve the physical
health of PLWD
 Studies that offer opportunities for transferable
learning such as those that evaluate interventions for
PLWD and other clinical conditions, or those that
look at the way services are delivered and
implemented for PLWD
 Published and unpublished studies of any design,
policy documents and guidelines.
The purpose of the searches was not to identify an ex-
haustive set of studies but rather to reach conceptual
saturation [21]. Search terms were devised in conjunc-
tion with an information scientist and were chosen to
reflect the theory areas identified in Phase 1. The
searches were split into three main categories: A — The-
ory areas + dementia AND diabetes, B — Theory areas +
dementia, C — Theory areas + diabetes. More details of
the searches are given in Table 1.
Selection and appraisal of documents
Search results were downloaded into bibliographic soft-
ware. Records and full-text papers were screened for in-
clusion by two of four reviewers (FB, PRJ, BR, DT). The
reviewers then met to discuss decisions and resolve any
disagreements. Decisions on inclusion made at different
points in time were recorded in an Excel spreadsheet.
Consistent with a realist synthesis approach, items were
assessed for inclusion on the basis of whether they were
considered ‘good enough and relevant enough’ [22, 23].
This was an iterative process that involved discussion
between team members. ‘Good enough’ was based on
the quality of evidence, for example whether it was of a
sufficient standard for the type of research, and whether
the claims made were considered to be trustworthy.
‘Relevance’ related to whether the authors provided suf-
ficient descriptive detail and/or theoretical discussion to
contribute to the theories generated in Phase 1.
Data extraction and synthesis
Data were extracted into a piloted ACCESS database;
the included fields reflected the theory areas identified
in Phase 1. Data were extracted by one reviewer, with
50% checked by a second. Data in a realist sense are not
just restricted to the study results or outcomes measured
but also include author explanations and discussions,
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which can provide a rich source of ‘data’ that makes ex-
plicit how an intervention was thought to work (or not).
The ACCESS database was used to identify prominent
recurrent patterns of contexts and outcomes (demi-re-
gularities) in the data and the possible means (mecha-
nisms) by which they occurred [24]. This deliberative
and iterative process enabled iteration from plausible hy-
potheses to the uncovering of potential context-
mechanism-outcome (CMO) configurations. The data
were discussed with the entire project team at a second
workshop.
Phases 3 and 4: test and refine programme theories
(validation) and develop actionable recommendations
To develop a final review narrative we reviewed the hy-
potheses through consultation with the Project Advisory
Group and with stakeholders. Stakeholder consultation
was done via telephone interviews (n = 7) and group dis-
cussions at a consensus conference (n = 24). Participants
at the conference were purposively sampled to ensure
that all the stakeholder groups in Phase 1 were repre-
sented. Following the consensus conference the CMOs
were revised and rechecked against data from the litera-
ture and stakeholder transcripts.
Results
We included 89 papers [8, 11, 12, 25–110]. These in-
cluded 79 research papers (22 reviews, 57 primary re-
search papers) and 10 guidelines or discussion pieces.
The 57 primary research papers reported 51 studies. Ten
papers focused on people living with dementia and dia-
betes (PLWDD), and the rest were concerned with dia-
betes (n = 32), dementia (n = 31) or other groups, such
as those with chronic illness or frailty. An overview of
the selection process is provided in Fig. 1 and a sum-
mary of included studies in Table 2. The majority of the
studies we included were from the UK (n = 33), North
America (n = 23) or mainland Europe (n = 11).
Our review resulted in six CMO configurations which
provide an explanatory account of how interventions
might work to improve the management of diabetes in
PLWD (see Table 3). Supporting evidence from stake-
holder interviews is provided in Table 4.
CMO 1: embedding positive attitudes towards PLWD
PLWD face problems accessing healthcare. This includes
a failure to design services around their needs, poor
communication between services, a lack of training on
dementia care for health and social care staff, and a reli-
ance on others (such as family carers) to recognise a
need for services and stigma [11].
Involving PLWD in self-management
Ten studies looked at self-management (SM) interven-
tions for PLWD or cognitive impairment (CI) [37, 41,
70, 73, 74, 80, 81, 88, 100, 104]. The evidence is limited,
as most focus on people living with mild or early stage
dementia, are mostly qualitative or small pilot or feasi-
bility studies, do not report measurable health outcomes
and usually focus on people with a partner [111]. Fur-
thermore, only one study, a controlled evaluation of per-
sonalised education sessions, included people with both
dementia and diabetes [37]. This US-based study found
a significant increase in self-efficacy but no difference in
glycated haemoglobin (HbA1c) levels at a 6 months
follow-up.
Despite this, these studies offer evidence and transfer-
rable learning for the development of SM support for
PLWDD. For example, confidence and a sense of control
appeared to be important mechanisms that could lead to
increased engagement in SM activities for PLWD [98].
Several studies suggested that supporting service users
and carers to become more functional, independent and
resilient was preferable to a purely clinical focus on
managing or treating medical symptoms [42, 54, 106].
Work on enablement suggests that there is a link be-
tween independence, functional ability and self-care be-
haviour, and feelings of confidence or self-efficacy in
PLWD and their family carers [39, 41, 98]. Working with
families is clearly key. However, studies highlight the
need to ensure that the voice of the PLWD is heard [81].
Qualitative studies on SM support for PLWD found that
information provision may be aimed at carers, leaving
PLWD feeling powerless [81], and that PLWD can find
support inappropriate or stifling [73, 100]. An overview
of context, mechanisms and outcomes for promoting
SM in PLWD is shown in Fig. 2.
CMO 2: person-centred approaches to care planning
PLWDD have two chronic life-limiting conditions with
different trajectories. Dementia generally has a progres-
sive or stepwise pattern of progression, whereas diabetes
may have a more constant course with longer periods in
which to adapt [112], but the trajectory of each is likely
to have an impact on the other. Delivering appropriate
and sustainable care for PLWDD from early stage to ad-
vanced dementia is a difficult clinical enterprise that re-
quires a change from a curative, biomedical strategy to a
more person-centred approach where patient priorities
are at the forefront [102, 113].
A recognition of patient motivators and goals and ne-
gotiation of a mutually agreed management plan could
improve adherence to SM regimens [26, 58, 65, 84, 93].
For example, maintaining independence and engagement
with day-to-day activities was a clear priority for partici-
pants in all groups (e.g. PLWDD, older people with
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diabetes, PLWD) [32, 37, 60, 78, 79, 100]. Several studies
suggested, however, that there was ‘goal divergence’ be-
tween patients, carers and HCPs, particularly when pa-
tient care was complicated by the presence of multiple
conditions [32, 58, 102].
Whilst continuity of care in long-term conditions such
as diabetes is known to be important, it assumes an
added significance for the PLWDD and their family. A
long-term trusting relationship is a key element to
achieving a person-centred approach to care that priori-
tises and values the patient’s subjective health experi-
ences [11, 26, 27, 31, 32, 43, 64, 65, 84, 93, 110]. People
with diabetes and CI are likely to need long-term
connection and maintenance programmes in order to
maintain positive impacts on glycaemic control [37].
Patient-centred communication and collaboration be-
tween healthcare professionals (HCPs) and patients/fam-
ilies appear to be key to achieving individualised care
[32, 58, 89, 102]. Several studies looked at the use of
tools, such as decision aids, for involving older people
with diabetes in shared decision making [35, 75, 89].
These did not show an impact on glycaemic control, but
the tools were thought to facilitate and provide structure
for patient-centred practice, co-construction of decision
making and patient engagement in their diabetes man-
agement. However, whilst such tools may be useful,
PLWDD are likely to need interventions which involve
more frequent contact and include repetition and
reinforcement. Decision making is likely to be compli-
cated by issues around consent, concordance and the ap-
propriateness of treatment.
CMO 3: developing skills to provide tailored and flexible
care
The literature highlights the importance of assessing the
specific self-care barriers faced by older people with dia-
betes, and tailoring advice and support to individual
needs and goals for diabetes SM [82, 94]. Clinical guide-
lines on diabetes recommend that target HbA1c levels
be relaxed for older people who are frail or have comor-
bidities and/or dementia [12, 114–116]. For example, a
Best Clinical Practice statement recommends that, for
PLWD, clinicians should aim to achieve a fasting blood
glucose 6–9 mmol/L, range (HbA1c 53–64 mmol/mol;
7–8%) [12]. Despite this, many older people with dia-
betes are potentially overtreated [8]. This could happen
partly because these targets do not ‘fit’ with current per-
formance measures [117] (such as Quality and Out-
comes Framework (QOF) targets in primary care in the
UK), or because HCPs do not always have the skills
needed to provide flexible individualised care for people
with diabetes and/or dementia [11]. Moreover, because
Fig. 1 Overview of study selection process
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SM support does not fit with a biomedically focused
ethos, it is not embedded in the day-to-day work of
primary care [60, 66–68, 85, 97].
A case study involving the use of continuous glucose
monitoring to measure hypoglycaemia in older adults
with diabetes found that simply relaxing HbA1c goals
may not be adequate to protect frail older adults against
hypoglycaemia. The authors concluded that there is a
need for treatment regimens that better match patients’
self-care abilities [83]. However, research suggests that
many HCPs do not take into account the abilities of pa-
tients and their family carers to cope with prescribed
treatment [32, 82].
CMO 4: regular planned contact
Planned, regular contact between HCPs and the PLWD
carers is needed in order for HCPs to anticipate transi-
tions and help PLWDD and their family carers to man-
age changes in function and SM capabilities [110]. This
is particularly important for PLWD where the dementia
may progress in an uneven pattern of decline [12, 36,
50] and where the transition from autonomy to delega-
tion or to caregiver-led management may be particularly
difficult [11, 26, 84]. In a trial focused on improving
diabetes management in older people, the authors
found that older adults were reluctant to make changes
to medication between clinic visits. However, regular
phone contact from a diabetes educator encouraged
people to adjust insulin dosage, leading to better
glycaemic control [82].
The studies in this review describe a range of interven-
tions delivered by a variety of HCPs: most commonly
general practitioners (GPs), nurses, occupational thera-
pists, psychologists and — in US studies — Certified
Diabetes Educators (CDEs). Regardless of who is deliver-
ing the intervention, studies consistently highlight the
importance of continuity and the quality of the patient-
clinician relationship [11, 37, 41, 46, 57, 82, 98]. Whilst
the quality of the relationship is important, PLWDD
need to be managed by practitioners with appropriate
expertise. Dementia as a comorbidity may challenge a
diabetes specialist, and a dementia specialist may lack
appropriate diabetes knowledge. Ensuring that all profes-
sionals have expertise in diabetes and dementia would
be difficult, and a collaborative practice is likely to be
necessary for people with both conditions, particularly
for more complex cases such as people who are insulin-
dependent or those with advanced dementia [91]. The
Table 2 Overview of included studies
Focus Methodological approach Types of outcomes
Diabetes AND dementia (n = 10)
• Clinical guidance on management of diabetes in PLWD
• Impact of dementia on self-management (SM)
• SM support for people with cognitive impairment (CI)
• 3 literature reviews
• 1 controlled (not randomised)
study
• 1 guideline
• 2 qualitative
• 1 description of a service
• 1 cross-sectional survey
• 1 mixed methods
• Glycated haemoglobin (HbA1c)
• Hypoglycaemia
• Impact of dementia on SM
Note that only one study evaluated
an intervention (Camp 2015)
Dementia NOT diabetes (n = 31)
Includes:
• SM support for PLWD
• Support for family carers
• Medication management
• Home-based support for PLWD (e.g. delivered by an occupational
therapist)
• Cognitive rehabilitation
Study type
• 9 qualitative
• 9 systematic reviews
• 7 randomised controlled trials
(RCTs, 3 papers report 1
study)
• 6 other
Patient outcomes include:
• Cognitive function
• SM-related behaviours such
as knowledge and self-efficacy
(but not diabetes focused)
• Quality of life
• Experiences and views
• Mood
Carer outcomes include:
• Carer stress, burden, quality of life
• Experiences and views
Diabetes NOT dementia (n = 32)
Participants include older adults, those with complex health needs
(comorbidity, frailty, etc.), people with mental illness and adults with type
2 diabetes mellitus
Includes:
• Interventions related to improving SM (e.g. use of assistive technology
(AT), SM support or decision aids)
• Better understanding the needs of people with diabetes
• 5 guidelines
• 9 other
(variety of study designs)
• 7 qualitative
• 5 RCTs
• 5 systematic reviews
• Glycaemic control
• Patient knowledge, self-efficacy
• Diabetes self-care practices
• Feasibility and acceptability
of interventions
• Quality of life
• Views and experiences
Other (e.g. people with chronic illness, frail older people,
people with multimorbidity or long-term condition) n = 15
Includes:
• SM support for conditions other than diabetes
• Service organisation
• Use of AT in older people
• 5 qualitative
• 4 RCTs
• 1 systematic review
• 4 other
• Views and experiences
• Self-care related outcomes
(e.g. knowledge, self-efficacy)
• Use of AT
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way in which specialists involved in the long-term care
of patients with dementia and diabetes or other long-
term conditions liaise with each other was recognised as
an issue, but was outside the remit of this review.
CMO 5: family engagement
There is a great deal of evidence that family members
often provide significant SM support for people with
long-term conditions such as diabetes [26, 64, 90], par-
ticularly when dementia affects a person’s ability to
undertake self-care-related tasks [110]. Family members
are also often proactive in facilitating continuity, negoti-
ating access to services for their relatives [11, 110] and
providing support or motivation for their relatives’ SM
activities [25]. Despite this, family carers often feel
undervalued or excluded from decision making, and they
may be ill prepared to take on responsibility for SM
[11, 26, 46, 47]. Problematic medication management
practices may persist despite the involvement of a
family carer [26, 71]. The situation is often further
complicated by the fact that carers may only take on
SM-related tasks once there is a crisis or a failure to
adhere to medication [47].
Managing the needs of a family member with diabetes
and dementia raises particular anxieties for carers
because of the risk of hypoglycaemia and other adverse
events associated with diabetes. Ensuring that their fam-
ily member eats appropriately and that this is coordi-
nated with their medication is a source of great concern
for carers, particularly if they are not co-located [11].
Inflexible service provision, such as district nurses being
able to go in only at certain times of the day or social
Table 3 The six context-mechanism-outcome configurations and supporting citations
Title Context Mechanism and outcome Included evidence
1. Embedding
positive attitudes
towards PLWD
If health and social care delivery systems
propagate and reinforce positive attitudes
towards people living with dementia and
diabetes (PLWDD) and their families,
through tailored self-management support
Then this fosters a belief in staff that PLWDD
have the potential to be involved in self-
management (SM) and the right to access
diabetes-related services (even when the tra
jectory is one of deterioration) (M) prompting
treatment confidence in PLWDD (M), which
leads to engagement in SM practices by
PLWDD and their carers (O)
[11, 12, 28, 37, 39–41, 53–55,
62, 67–70, 73, 74, 80, 81, 88, 99,
100, 102, 104, 110]
2. Person-centred
approaches to
care planning
If delivery systems promote a person-centred
and partnership approach to care, allowing
healthcare professionals (HCPs) to understand
the individual needs and abilities of PLWDD
and their family
Then (1) HCPs feel confident that they are
acting in the best interests of PLWDD and
family (M), and this (2) generates trust
between HCP and PLWDD/family (M),
leading to better fit between care planning
and patient and carer needs and (potentially)
a lessening of the burden of medicalisation
experienced by PLWDD and their families (O)
[26, 27, 31, 35, 37, 42, 43, 52–
54, 58, 60, 62, 64, 65, 72, 75, 79,
82, 84, 89, 90, 93–95, 98, 100,
102, 105, 106]
3. Developing
skills to provide
tailored and
flexible care
If HCPs are expected to develop skills that
enhance the delivery of individualised and
tailored care to PLWDD (e.g. enablement
rather than management, listening/
communication/negotiation)
Then this legitimates the work creating the
expectation in patients and HCPs that the
management of diabetes for PLWD is
important (M), leading to the provision of
more tailored diabetes care (O) and better
engagement in self-management by PLWDD
and family carers (O)
[8, 26, 35, 44, 45, 58, 62, 64, 75,
78, 79, 82, 83, 85, 89, 91, 97,
102]
4. Regular contact If HCPs maintain regular contact over time
(e.g. face-to-face, telephone, e-mail) with the
PLWDD/family, monitoring and anticipating
needs throughout the dementia trajectory
Then HCPs feel more equipped to meet
patient needs (M), and PLWDD/family believe
themselves to be supported (M) through
transition from functional independence
to functional dependence (M), leading to
improved diabetes management (O)
[12, 26, 34, 36–38, 41, 43, 46,
57, 82–86, 92, 96, 98]
5. Family
engagement
If family carers are routinely involved in care
planning and information sharing and are
given the support they need to take on the
tasks associated with managing diabetes in
PLWD (e.g. medication management,
recognition of hypoglycaemia)
Then family carers will feel supported and
believe their contribution is recognised and
appreciated (M), leading to the development
of effective self-management strategies on the
part of the family carers (O)
[11, 25, 26, 31, 33, 46, 47, 53,
64, 71, 72, 81, 92, 98, 110]
6. Usability of
assistive devices
As the dementia trajectory progresses, assistive
technology needs to be tailored and adapted
to the needs and requirements of PLWDD
and family (includes social, environmental
and cultural needs) with the focus on
maintaining autonomy for the PLWDD
This leads to PLWDD and family gaining
awareness of the usefulness of assistive
technology in their management of diabetes
and dementia (M), leading to more effective
and sustained use of assistive technology to
maintain autonomy and diabetes self-
management strategies (O)
[11, 25, 34, 37, 48, 49, 51, 56,
59, 63, 69, 76, 77, 87, 95, 101,
103]
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Table 4 Examples of supporting evidence from stakeholder interviews
CMO Examples of supporting evidence from stakeholder interviews
1. Embedding positive
attitudes towards PLWD
• “…you shouldn’t be sort of swayed one way or the other, just because someone has dementia…
I think certainly when they first start on their journey I think it’s really important that we do everything
we can…” [of cross-disciplinary training to facilitate appropriate care], Diab1
• “…an intervention should work at a level that people…particularly early stages of dementia…
can be included…so it’s not decisions being made about them…”, Dem1
• “…the Getting To Know Me project here in XXX we trained over six hundred, or seven hundred,
frontline practitioners about dementia, just a general aspects of dementia, what it is, how to communicate,
what to look for, what people might be saying when they maybe can’t tell you through words…”, Dem7
2. Person-centred approaches
to care planning
• “But actually at this stage (referring to when people have complex health needs) people are interested in
autonomy, mobility you know, retaining as much function and independence as they can, being a burden
on their families you know, so all the normal things and they’re often much, much more important than
a lot of the medical stuff”, Diab12
• “It’s allowing a two-way exchange of information isn’t it about how different conditions might affect things.”,
Res1
• “Where the client is fully able to contribute [to a care plan], that usually goes very well because we can then
discuss the likes and dislikes, their routines, how they manage their diabetes themselves…”, Dem4
• “I think different targets for certain groups of people you know, and quality of life targets rather than
all about number crunching…”, Diab13
3. Developing skills to provide
tailored and flexible care
• “…we encourage people to set agreed targets with the patient…that may well be…higher than the general
population target which is a key message we get across to the GPs because they’re so driven by QOF”, Diab9
• “I don’t think we’re supporting people with diabetes [and dementia] as well as we could, because of this
training issue and where responsibility lies…”, Dem4
• “I’ve seen very very few examples where it’s done well, any of this, any of this sort of self-management,
shared decision-making, anything. …..I think health professionals are possibly becoming themselves much
more risk-averse and not wanting to suggest things that aren’t perceived as being healthy or might not be
the right answer”, Res1
• “choosing wisely American stuff you know, I think we’re all warming up to this agenda but I don’t think
anyone’s quite cracked you know, it’s not mainstream yet.”, Diab12
• “…for the general population, self-management…is not working particularly effectively…translate that to a
much more delicate and fragile group…who have other comorbidities and have dementia…then those types
of responses are likely to be even less effective …” [of SM support strategies], Diab2
• “…one of my profound frustrations is that you can have people talking about multiple long-term conditions
and they’re excluding mental health diagnoses, and yet we know that you know, 30% to 40% of people with
diabetes will have anxiety and depression you know, and often early unrecognised memory issues…”, Diab12
4. Planned regular contact • “…if it’s set up on a regular basis, so the person knew, you know, like Tuesday afternoon’s when I speak to my
diabetic nurse, that can be put in their diary.”, Dem4
• “since I’ve been in the care of the Diabetic Clinic everything else has gone out the window. When I was in the
care of the specialist nurse at the GP’s, I would have a regular sort of every six month check on my feet…and the
amount of protein in my urine, all those tests have now ceased, I’m now only looked at from a point of view of
sugar levels.”, Person with type 2 diabetes mellitus
• “…if you have one healthcare person who you know is almost like your keyworker, your key contact,
you build up a relationship, which is very important…”, Diab4
• “…I have a very good colleague…who is a specialist physical healthcare nurse and a mental health nurse,
and that is a, I’ve often thought of this person as a really interesting model for the future…”, Dem7
5. Engaging with families • “…I think we could probably do a lot more…supporting families and carers and to give them the confidence,
I think they’re so worried, it can be so… frightening…to have both conditions…”, Diab13
• “… patients are educated one to one or through diabetes-structured education, again I’ve never heard of a
patient education for carers and those with dementia to support them…”, Diab11
• “We need to sort of normalise the situation where it is completely normal and expected that close family
members will be involved in any decisions and there will be partnership”, Researcher, self-management of
long-term conditions
6. Usability of assistive
technology
• “… there’s electronic dosette boxes…linked to telecare, so if the person doesn’t take the medication,
telecare will come through the intercom and say, ‘Mr so and so, you need to take your tablets’, and then
if they don’t …[it] locks anyway so they can’t overdose”, Dem2
• “I was familiar with the sort of dosette box, if that’s what you’re talking about, which is a great idea and
does really help people”, Dem1
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services carers not having the authorisation to oversee
medication for people with diabetes, is an additional
concern [11, 110].
Although we found no studies evaluating structured
interventions to provide education and support to family
carers of PLWD, qualitative studies looking at SM for
PLWD [81] and for people with diabetes (not dementia)
[64] argue that it is important to involve carers in the
development of SM skills alongside the person they care
for. Interventions aimed at supporting PLWD to manage
their diabetes should take into account the education
and support needs of family carers as well as the PLWD
[11, 26, 46]; this support needs to include the issues aris-
ing from both conditions and the way dementia is likely
to affect diabetes management [11].
CMO 6: usability of assistive technology
For the purpose of this CMO, assistive technology (AT)
is defined as ‘any product or service designed to enable
independence for disabled and older people’ [118]. We
included 17 papers (five of which were systematic re-
views) in this section. Two relate to PLWDD [11, 37],
seven relate to the use of AT in PLWD [34, 48, 49, 51,
63, 69, 95], four concern the use of AT in older people
[56, 87, 101, 103] and four involve people with diabetes
(not dementia) [25, 59, 76, 77]. Current evidence
suggests that AT may facilitate communication and
access to support and information for carers, but that it
has little impact on independence, safety or security for
PLWD. There are also issues with the performance of
the technology and acceptability to users [48].
AT such as biometric monitoring, medicine manage-
ment reminders and sensors and alarms to track move-
ment is seen as one way of maintaining autonomy for
PLWD [103]. The use of simple technology such as
dosette boxes can also be used to maintain independ-
ence, although these tools are likely to become less suc-
cessful as the dementia progresses [110]. AT provision
often involves the direct purchase of ‘off-the-shelf ’
technology which is adapted by family carers [49, 56]. A
review of AT for PLWD found that family carers were
most likely to use technology not specific to caring or to
dementia, such as tablets, baby monitors, smart phones
or light sensors [69].
Family carers played a significant role in supporting
the use of AT [48, 49, 76, 77, 87, 101, 110]. They helped
to embed AT, reduce patient anxiety [49] and increase
motivation and participation [25]. However, a feasibility
study of diabetes self-care support suggests that family
ties are complex and that family involvement in SM is
not always helpful [77]. There is evidence that PLWD
wanted to and could contribute to the design of AT, and
Fig. 2 Overview of identified context, mechanisms and outcomes for self-management programmes in PLWD
Table 4 Examples of supporting evidence from stakeholder interviews (Continued)
• “But, I mean some of the insulin pens are really fiddly as well, like they’ve got really tiny numbers and you have
to dial it up and all that kind of thing, I don’t know how well they’re adapted for people with visual problems or
cognitive problems.”, Dem6
• “In one local authority, we went to one recently, a dementia kind of carers group and sat with them and
showed them a list from somewhere else and some of the devices on that weren’t on theirs, you know?
It’s not equitable…”, Res2
• “…technologies are great but you need to think is it the right thing for the patient…is there enough support
around it to implement it and respond to it …”, Res2
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commentators argue that this makes it more likely to ‘fit’
with the needs of the PLWD [95]. However, even when
they are involved in the design of AT, PLWD are likely
to need on-going support and family involvement [101].
Technology in itself is unlikely to solve the problem of
independent living for older people [56], particularly for
those living with dementia [69, 119]. Technology
appears to be most effective when it augments or
involves face-to-face contact [34, 37, 48, 59].
Summary of CMOs
The six CMO configurations are summarised in Fig. 3.
The CMOs are grounded in evidence from the literature
and stakeholder perspectives. Although designed to be
specific to PLWD, the CMOs are also likely to be trans-
ferable to other groups who experience problems with
diabetes management, for example older people with
complex health and social care needs. The CMOs are
not mutually exclusive, and we would suggest that what
is most important is how the different elements of each
interact. The CMO configurations require changes in in-
dividual or organisational behaviour or understanding,
and in many cases both. For example, CMO 3 — which
focuses on skills development — requires the develop-
ment of skills at an individual level but also organisa-
tional changes which legitimise the importance of those
Fig. 3 Summary of the six CMO configurations that make up the programme theory
Bunn et al. BMC Medicine  (2017) 15:141 Page 12 of 18
skills and allow the time for them to be acquired and
practiced. The outcomes we specified in the protocol for
this synthesis included a number of clinical outcomes,
such as the prevention of hypoglycaemia, the manage-
ment of cardiovascular risk factors and the identification
and management of long-term complications such as
neuropathy. However, the outcomes that emerged from
the evidence available are primarily experiential rather
than clinical, focusing on the need to trigger mecha-
nisms such as trust, confidence and empowerment.
Discussion
Summary of findings
An overarching contingency emerges from the data that
relates to the convergence or alignment between an
intervention strategy, disease progression and social and
environmental factors, in particular the involvement of
family carers. In the early stages, where the PLWDD can
still retain some functionality to make decisions about
their diabetes management, ‘personalisation’ and ‘rela-
tionship’ building are key components of care that in-
volve the PLWDD, their family carer and the HCPs. This
requires a re-orientation of staff capabilities towards
prioritising PLWDD and family perspectives over bio-
medical directives. As the dementia trajectory progresses
and independent functioning becomes more problematic
for the PLWDD, affecting SM behaviours, then there
may be a need to move towards greater ‘monitoring’ by
the HCP and family carer. This risk-management per-
spective may use technology as a way of maintaining
confidence in diabetes SM, but we found no evidence to
suggest that it can compensate for the loss of cognitive
ability. The relationship and personalisation perspectives
are essential throughout the trajectory, but they are
adapted to anticipate the changing needs of PLWDD
and their family carers.
Implications of the findings
This review highlights the way that emotional support
and practical assistance provided by families is key for
PLWDD. Despite this, carers often feel undervalued or
ill prepared to take on caring responsibilities. A survey
of carers of older people with diabetes found that 40% of
family carers had never received any information on dia-
betes from professionals [120]. Many of the support
needs of family carers identified could equally apply to
PLWD and other comorbidities. However, there are
clearly some concerns that are particularly pertinent to
family members of PLWDD. Whilst many carers may
find medication management stressful, this task is often
exacerbated for family carers of PLWDD owing to their
concerns about the prevention of adverse events
associated with either hypoglycaemia or hyperglycaemia
[11, 46, 110]. Family carers are likely to need education
combined with on-going support from a specialist in
diabetes [12]. They may also have needs related to the
dementia, such as how to manage behaviours that
challenge.
There is little evidence on which to base any recom-
mendations for practice for PLWDD who have very
limited networks of support from family or friends.
Research suggests that PLWD who live alone have an
increased risk for unmet social, environmental, psycho-
logical and medical needs [121] [11]. Our CMO on
person-centred approaches to care planning identified
the generation of trust between the HCP and the PLWD
as necessary in order to improve care planning and SM.
Building trusting relationships with HCPs may be
particularly important for those who live alone, as they
do not have a family member to facilitate access and
continuity of care [11] and are likely to be more
dependent on HCPs to perform this role [122]. However,
PLWD who lived alone found it difficult to trust others
and admit to their mistakes or challenges, because they
feared being placed in long-term care [123].
Person-centred care is a consistent feature of our
programme theory. It is identified as a trigger for
mechanisms such as trust, empowerment and a belief
that SM is achievable and worthwhile for people with
dementia and diabetes. These ideas are not new, as guid-
ance for both conditions recommends person-centred
care [61, 124, 125]. What this synthesis does is begin to
identify some of the key components of person-centred
diabetes care for people with dementia and the organisa-
tional and practice changes this might entail. For
example, the instigation of individualised (possibly
simplified) diabetes regimens requires that the PLWDD
sees an appropriate specialist/s or that generalists such
as GPs and practice nurses have appropriate knowledge
about how to tailor diabetes care. It presupposes inter-
professional approaches to clinical decisions and regular
review of care. It also relies on HCPs knowing that such
actions are legitimised, for example through less focus
on biomedical targets and time allocation to establish an
understanding of the individual’s story and priorities.
This is inevitably linked to continuity and having a prac-
titioner who both understands the dementia trajectory
and can also respond as care needs alter [11].
A UK study found that PLWD had an average of 4.6
chronic diseases in addition to their dementia [126],
meaning that diabetes may be only one of several health-
care concerns for older people with dementia. In
addition, diabetes and frailty are closely interrelated
[127], and the relationships between hypoglycaemia,
frailty and dementia appear to be reciprocal, with each
condition potentially exacerbating the others [8]. Guide-
lines on diabetes care in older people and those with
dementia emphasise the need to consider the
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significance of frailty and the need to avoid
hypoglycaemia [12, 114]. Despite this, there is evidence
that a substantial proportion of older adults are poten-
tially overtreated [128]. Performance measures should
incentivise appropriate de-intensification as well as in-
tensification of medication regimens [8], and research is
needed to consider whether care pathways for this group
need to be specific to diabetes and dementia or whether
a pathway for older adults with complex needs, such as
frailty or multimorbidity, is more appropriate.
Strengths and limitations
The main limitation of this study was the lack of evi-
dence relating specifically to the management of diabetes
in PLWD. This lack of evidence is compounded by few
insights into how the point at which the person develops
dementia or diabetes affects treatment. However, in real-
ist methodology the unit of analysis is the programme
theory, or underpinning mechanism of action, rather
than the intervention [129]; as such we were able to
draw on a wider body of literature that provided oppor-
tunities for transferable learning. This enabled us to
develop a theory-driven explanation in the form of six
CMO configurations that can be used to guide future
initiatives and interventions.
The outcomes in our CMOs are largely experiential
rather than clinical. This reflects the evidence available.
Outcomes such as increased engagement in SM are
potential surrogates for better clinical management of
diabetes, but this is not proven. The literature suggests
that key goals for this group are maintaining independ-
ence and creating treatment regimens that ‘fit’ with the
needs and abilities of the PLWD and family carer.
However, literature in this area is scarce, and further
work is needed to identify what it is that PLWDD and
their family carers want from interventions [130].
Much of the evidence we included related to either
PLWD or people with diabetes, rather than people with
both conditions. Inevitably, the aims, focus and out-
comes of these two sets of studies are very different.
Moreover, because we drew on this larger literature,
there were many more potentially relevant sources of
information than we could possibly cover. However, the
nature of realist synthesis means that there is not a finite
set of relevant papers to be found. Rather the reviewer
takes a more purposive approach to sampling [129], with
the aim of reaching conceptual saturation rather than
identifying an exhaustive set of studies [21].
Many of the conclusions in this review about diabetes
care are not specific to people with dementia. For
example, personalised approaches to medication choice,
continuity of care and a focus on individual patient pref-
erences are relevant to all age groups [131, 132]. The
review shows, however, how a diagnosis of dementia
creates extra and different needs from those experienced
by people with diabetes but without dementia. People with
dementia and diabetes are more likely to be dependent on
support from unpaid carers, may have more trouble acces-
sing diabetes-related healthcare [11] and are at greater risk
of complications such as hypoglycaemic episodes. Future
research should consider the impact of involving family
carers in SM interventions for people with diabetes and
dementia, look at ways to improve medication manage-
ment and explore how professionals can recognise when a
person is no longer able to self-manage and provide
appropriate support.
Conclusions
The challenge for HCPs is how to accommodate quality
of life, independence and patient and carer priorities
with the minimum requirements of ‘good’ diabetic con-
trol. We recognise that perceptions of ‘good’ are
situation-specific, differ for PLWDD and for family
carers and will change over time. This review suggests
that there is a need for a further work to establish a
shared understanding of what needs to be in place to en-
gage effectively with PLWD including those with dia-
betes and their supporters to establish how ‘good
support’ is operationalised and measured. Much of the
research included in this review, particularly that specific
to PLWDD, identifies deficiencies and problems with
current systems. Whilst we have highlighted the need
for personalised care, continuity and family-centred ap-
proaches, there is much evidence to suggest that this is
not currently happening. Future research on the man-
agement of diabetes in older people with complex health
needs, including those with dementia, needs to look at
how organisational structures and workforce develop-
ment can be better aligned to their needs. The role of
family carers in managing healthcare conditions of
PLWD and their contribution in facilitating continuity
and access to care are indisputable [11]. It is important,
therefore, that HCPs conceptualise the provision of care
for PLWD and a comorbidity as a complex phenomenon
that affects not just individuals but also dyads and
families [90].
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